Company Overview of Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. operates as a cardiovascular drug development company that develops novel small molecule therapeutics. It offers a novel and potent short-acting calcium channel antagonist for the treatment of transient cardiovascular conditions, such as paroxysmal supraventricular tachycardia by the termination of acute episodes of atrial tachycardia in patients. The company was founded in 2005 and is based in Saint-Laurent, Canada.
1111 Dr.-Frederik-Philips Boulevard
Saint-Laurent, QC H4M 2X6
Founded in 2005
Key Executives for Milestone Pharmaceuticals Inc.
Chief Executive Officer and Director
Vice President of Corporate Development
Vice President of Chemistry & Manufacturing
Compensation as of Fiscal Year 2016.
Milestone Pharmaceuticals Inc. Key Developments
Milestone Pharmaceuticals Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:30 PM
Jan 30 16
Milestone Pharmaceuticals Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:30 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States.
Milestone Pharmaceuticals Inc. Announces United States Adopted Name Approval of Generic Name "Etripamil" for Phase 2 Clinical Development Product
Jan 25 16
Milestone Pharmaceuticals Inc. announced that United States Adopted Name (USAN) Council recently adopted "etripamil" as the unique non-proprietary or generic name for MSP-2017. The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships. Etripamil is being developed as a patient self-administered intranasal spray to terminate paroxysmal supraventricular tachycardia (PSVT) at the onset of episodes and is currently being evaluated in a Phase 2 clinical trial (NODE-1) in the United States and Canada. Etripamil is a novel and potent short-acting calcium channel antagonist intended for the treatment of patients with PSVT, a potentially debilitating cardiac arrhythmia. Phase 1 results showed that etripamil had a rapid onset and reached pharmacologically relevant plasma levels within 5 minutes of administration. Etripamil is designed to be short-acting and metabolized quickly after resolution of the PSVT episode to avoid the potential complications of current long-term therapies. Etripamil is intended to address an important unmet medical need in patients who demand a convenient, rapidly efficacious and safe self-administered product for the treatment of PSVT episodes in the home setting.
Milestone Pharmaceuticals Inc. Presents at BIO-Europe Spring 2016, Apr-05-2016 02:45 PM
Jan 20 16
Milestone Pharmaceuticals Inc. Presents at BIO-Europe Spring 2016, Apr-05-2016 02:45 PM. Venue: Kistamässan Convention Center, Stockholm, Sweden.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries